2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P2459
    MOG (35-55), human 163158-19-8 98.93%
    MOG (35-55), human is a component of CNS myelin. MOG (35-55), human is different from mMOG (35-55) by a proline for serine substitution at position 42. MOG (35-55), human is also immunogenic via bind to H-2b class II MHC and recognized by T cells, but not encephalitogenic, and is only partially cross-reactive with mMOG35–55. MOG (35-55), human induces minimal clinical signs of EAE relative to the rodent peptide.
    MOG (35-55), human
  • HY-17498S
    Atenolol-d7 1202864-50-3
    Atenolol-d7 is the deuterium labeled Atenolol. Atenolol ((RS)-Atenolol) is a cardioselective β1-adrenergic receptor blocker, with a Ki of 697 nM atβ1-adrenoceptor in guine pig left ventricle membrane. Atenolol can be used for the research of hypertension and angina pectoris[1][2].
    Atenolol-d7
  • HY-10302
    MK-3207 Hydrochloride 957116-20-0 98.02%
    MK-3207 (Hydrochloride) is a potent and orally bioavailable CGRP receptor antagonist with IC50 of 0.12 nM and Ki of 0.024 nM, and is highly selective versus human AM1, AM2, CTR, and AMY3.
    MK-3207 Hydrochloride
  • HY-10412
    CEP-1347 156177-65-0 ≥98.0%
    CEP-1347 is an inhibitor of the JNK/SAPK pathway with neuroprotective effects. CEP-1347 blocks JNK1 activation induced by members of the mixed lineage kinase (MLK) family (MLK3, MLK2, MLK1, dual leucine zipper kinase, and leucine zipper kinase). As an inhibitor of MDM4, CEP-1347 can more effectively inhibit the growth of glioma cells expressing wild-type p53.
    CEP-1347
  • HY-10457
    Velusetrag 866933-46-2 99.91%
    Velusetrag (TD-5108) is an orally active, potent and selective agonist of serotonin 5-HT4 receptor (5-HT4R), with a pKi of 7.7. Velusetrag exhibits no affinity (Ki>10 μM) for 5-HT2A and 5-HT2B receptors. Velusetrag can be used for the research of gastrointestinal diseases and Parkinson's disease.
    Velusetrag
  • HY-12282
    GNE-9605 1536200-31-3 99.72%
    GNE-9605 is a potent, orally active, selective Leucine-rich repeat kinase 2 (LRRK2) inhibitor with an IC50 value of 18.7 nM. GNE-9605 inhibits LRRK2 Ser1292 autophosphorylation. GNE-9605 can be used in research of Parkinson's disease (PD) .
    GNE-9605
  • HY-12436
    NTRC-824 1623002-61-8 98.2%
    NTRC-824 (Compound 5) is a potent, selective and neurotensin-like nonpeptide neurotensin receptor type 2 (NTS2) antagonist with an IC50 of 38 nM and a Ki of 202 nM. NTRC-824 is >150-fold selectivity for NTS2 over NTS1 (Ki >30 μM).
    NTRC-824
  • HY-12713
    Lisuride 18016-80-3 99.85%
    Lisuride is an orally active dopamine D2 receptors agonist. Lisuride, as an ergot derivative, can be used for the research of Parkinson's disease, migraine, and high prolactin levels.
    Lisuride
  • HY-12809
    Optovin 348575-88-2 99.81%
    Optovin is a reversible photoactivated TRPA1 ligand that enables light-mediated neuronal excitation. Optovin activates TRPA1 via structure-dependent photochemical reactions with redox-sensitive cysteine residues.
    Optovin
  • HY-13044
    ADL-5859 hydrochloride 850173-95-4 99.77%
    ADL-5859 hydrochloride (compound 20) is a selective and orally active δ opioid receptor (DOR) agonist with an Ki and an EC50 value of 0.84 and 20 nM, respectively. ADL-5859 hydrochloride also shows inhibitory activity to hERG channel with an IC50 value of 78 μM. ADL-5859 hydrochloride can be used for the research of pain.
    ADL-5859 hydrochloride
  • HY-13288
    Org 27569 868273-06-7 99.75%
    Org 27569 is a potent CB1 receptor allosteric modulator, which increases agonist binding, yet blocks agonist-induced CB1 signaling.
    Org 27569
  • HY-14167
    GW842166X 666260-75-9 99.97%
    GW842166X is a potent and selective cannabinoid receptor 2 (CB2) agonist with IC50 values of 63 and 91 nM for human and rat CB2, respectively.
    GW842166X
  • HY-14339
    Intepirdine 607742-69-8 98.92%
    Intepirdine (SB742457) is a highly selective 5-HT6 receptor antagonist with pKi of 9.63; exhibits >100-fold selectivity over other receptors.
    Intepirdine
  • HY-14562
    TBPB 634616-95-8 99.74%
    TBPB (tert-butyl peroxybenzoate) is a highly selective, blood-brain-permeable M1 mAChR allosteric agonist (EC50=289 nM) with anti-schizophrenia and anti-inflammatory activities. TBPB can enhance the sensitivity of M1 receptors to acetylcholine, activate downstream signaling pathways, and inhibit the release of pro-inflammatory cytokines (TNF-α, IL-6). TBPB can regulate the processing of amyloid and can be used in the study of neurodegenerative diseases (such as Alzheimer's disease) and inflammation-related diseases (such as sepsis).
    TBPB
  • HY-14785
    Befiradol 208110-64-9 99.20%
    Befiradol (NLX-112) is a selective 5-HT1A receptor agonist.
    Befiradol
  • HY-18172
    KCC2 blocker 1 1228439-36-8 98.24%
    KCC2 blocker 1 is an orally active and selective K+-Cl- cotransporter KCC2 blocker with an IC50 of 1 μM. KCC2 blocker 1 is a benzyl prolinate.
    KCC2 blocker 1
  • HY-19371
    Lorediplon 917393-39-6 99.88%
    Lorediplon is a novel non-benzodiazepine drug acting as a GABAA receptor modulator, differentially active at the alpha1-subunit, associated with promoting sleep.
    Lorediplon
  • HY-19411
    SSR180711 hydrochloride 446031-79-4 99.90%
    SSR180711 hydrochloride is an orally active, selective and reversible α7 acetylcholine nicotinic receptor (n-AChRs) partial agonist. SSR180711 hydrochloride can act on rat α7 n-AChR (Ki=22 nM; IC50=30 nM) and human α7 n-AChR (Ki=14 nM; IC50=18 nM). SSR180711 hydrochloride increases glutamatergic neurotransmission, ACh release and long-term potentiation (LTP) in the hippocampus.
    SSR180711 hydrochloride
  • HY-34611
    Boc-L-2,4-Diaminobutyric acid 25691-37-6 ≥98.0%
    Boc-L-2,4-Diaminobutyric acid is a derivative of L-2,4-Diaminobutyric acid (HY-101414)[1.
    Boc-L-2,4-Diaminobutyric acid
  • HY-75095
    (S)-(-)-1-Phenylethanamine 2627-86-3 ≥98.0%
    (S)-(-)-1-Phenylethanamine (S-(-)-α-Phenylethylamine; L-(-)-α-Methylbenzylamine) is a S-isomer of 1-Phenylethanamine (HY-W012848). 1-Phenylethanamine is a potential central nervous system stimulant and can be used to synthesize the tyrosine kinase inhibitor CLM3 (HY-164413).
    (S)-(-)-1-Phenylethanamine
Cat. No. Product Name / Synonyms Application Reactivity